Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5Terminated 3Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 53Lymphoma, Mantle-Cell 34Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Follicular 18Lymphoma 15Lymphoma, Non-Hodgkin 13Waldenstrom Macroglobulinemia 12Lymphoma, B-Cell 12Recurrence 9Lymphoma, B-Cell, Marginal Zone 9Leukemia 6Bronchiolitis Obliterans Syndrome 6Multiple Myeloma 5Leukemia, Lymphoid 5Leukemia, B-Cell 5Hodgkin Disease 5Hematologic Neoplasms 4Burkitt Lymphoma 4Neoplasms 3Graft vs Host Disease 3Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Chromosome 17 deletion 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × ibrutinib × Clear all
NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Alliance Foundation Trials, LLC.

Phase 1 Completed
14 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Sumitomo Pharma America, Inc.

Phase 1 Completed
15 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01962792 2021-12-21

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Pharmacyclics LLC.

Phase 1/2 Completed
84 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT02902965 2020-03-16

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Pharmacyclics Switzerland GmbH

Phase 2 Completed
74 enrolled 20 charts
Plasma cell

Multiple Myeloma

NCT01478581 2020-03-10

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Pharmacyclics LLC.

Phase 2 Completed
92 enrolled 21 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡